Feb 9, 2026 09:46AM
Feb 9, 2026 06:37AM
Feb 4, 2026 07:30AM
Feb 4, 2026 07:30AM
Jan 25, 2026 11:52PM
Jan 25, 2026 06:30PM
Jan 25, 2026 06:30PM FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Nov 26, 2025 06:03AM
Nov 25, 2025 07:31AM
Nov 25, 2025 07:30AM
Oct 31, 2025 03:37AM
Jul 31, 2025 03:14PM
Jul 30, 2025 11:00AM
Jul 30, 2025 11:00AM Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 30, 2025 11:00AM
Jul 30, 2025 09:00AM
Jul 30, 2025 09:00AM
Jul 30, 2025 08:07AM
Jul 20, 2025 08:00PM
Jun 13, 2025 11:43AM
May 15, 2025 10:47AM Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
Feb 13, 2025 07:39AM
Jan 26, 2025 06:54PM
Jan 26, 2025 06:33PM
Jan 26, 2025 06:30PM
Jan 13, 2025 07:03PM
Dec 11, 2024 09:44AM
Oct 31, 2024 08:03PM Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the F
Aug 6, 2024 06:46AM
Jun 9, 2024 10:13PM
Jun 9, 2024 07:37PM
Jun 9, 2024 07:30PM
Jun 12, 2023 05:30AM
Jun 9, 2023 06:45PM
Jun 1, 2023 12:55PM Goldman Sachs on Biogen (BIIB): 'we remain positive on BIIB's opportunity to address the early AD market'
Jun 1, 2023 08:56AM
May 1, 2023 08:43AM
Apr 26, 2023 03:16PM
Apr 25, 2023 07:52AM
Mar 31, 2023 05:50AM
Mar 30, 2023 07:31PM
Mar 30, 2023 07:30PM EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Mar 30, 2023 07:30PM
Mar 30, 2023 07:30PM
Mar 22, 2023 08:31PM
Mar 22, 2023 08:31PM
Mar 8, 2023 06:30AM
Mar 6, 2023 07:01AM
Mar 5, 2023 06:30PM FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disea
Mar 5, 2023 06:30PM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All